Review
Open access
Jul 2026
Anaplastic thyroid cancer: review of precision therapy options and advances.
A patient with advanced BRAF-mutant ATC who recovered with a combination of the anti-PD1 nivolumab and the BRAF V600E targeted drug vemurafenib is shown, indicating further studies using biomarker-based gene- and immune-targeted agents, including in combination, are needed in ATC.
Noor Khalid, R. Kurzrock, Shumei Kato
· npj Precision Oncology · 1 citation